Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
about
Severe events in donors after allogeneic hematopoietic stem cell donationThe importance of the granulocyte-colony stimulating factor in oncologyComparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.Racial and ethnic differences in risk of second primary cancers among breast cancer survivorsTrial Watch-Immunostimulation with cytokines in cancer therapyTherapy-related myeloid neoplasms: pathobiology and clinical characteristicsIdentifying specific chemotherapeutic agents in Medicare data: a validation studyDrug-induced hematologic syndromesCongenital neutropenia: diagnosis, molecular bases and patient management.Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicinLower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation.A health services research agenda for cellular, molecular and genomic technologies in cancer care.Breast cancer and the immune systemProphylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis.Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial.Trial watch: Immunostimulatory cytokines in cancer therapy.Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapyIncreased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005.Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition.Acute myeloid leukemia of donor origin after allogeneic stem cell transplantation from a sibling who harbors germline XPD and XRCC3 homozygous polymorphisms.The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools.Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancerTherapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.Is Chemoendocrine Treatment without Alternative?Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012).Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic CoAlteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.Breast cancer survivorship issues.Building capacity to assess cancer care in the Medicaid population in New York State.G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use.Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries.Clinical pharmacology of chemotherapy agents in older people with cancerBreast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.Second malignancies among elderly survivors of cancer.Effects of granulocyte-colony-stimulating factor on Monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donors.Incidence of acute myeloid leukemia after breast cancer.Adjuvant trastuzumab in HER2-positive breast cancer.
P2860
Q24649646-E20D21F2-5411-4BF9-A753-E43095BEAA32Q26770908-0D573FF8-5461-4067-B6DD-664A4CD8BF2AQ27001627-75579022-604E-46C7-B89D-9E2B518B9F21Q27317129-E4C6BF2B-FABA-4D0E-8E90-6199B2D9A88DQ28078725-250C09CF-A90D-4A6B-A769-215C74037F85Q28386366-C980ED34-2B18-4377-9C57-9E15F6CEBF0BQ30413422-033738BB-3A2C-47E2-A89B-71896B603F29Q33387312-B1A0CC08-3B66-44BF-87C5-59ED54B4F45FQ33395402-4885F8A6-3072-44C8-8A74-C99C7D736AA5Q33422353-45097170-4013-4E29-985C-195E88748C4DQ33718833-9D97B5A6-EA5D-4E48-866D-AF723FDFF584Q33749983-829C6654-BCF0-4FB6-BE0E-82690E1F3C52Q33753043-F3533B16-16F5-41EB-AEEC-3EB1C22EB02AQ33756369-6FC5DE40-E35F-432A-BAD7-5175903055B6Q33780538-75ECFF2C-82EF-4C23-BA12-CBCFD2CE7932Q33871452-0616EBF1-BADE-40AD-B7F6-EFEDB9C4F5F2Q33880165-CFEDA482-30BE-43E8-833A-DBEF0415800AQ33928011-0807E609-35C8-42DF-93B3-FE640C4D1A53Q33938533-9B8992E3-1FA3-4EBD-BD2D-940336CA4A27Q33968055-6BE4C48A-360E-4603-ABD8-127280EF63CEQ34032840-77ED0AB7-5B59-4F89-8C91-862BE625EB65Q34095827-1F464D2F-9FEA-48AC-886A-1276DACDBD86Q34252411-40DCCA64-5DB3-4FD0-8338-8BD472DFA72EQ34267862-0DD2E88D-011A-40B7-9B24-B43522998D66Q34284263-6CE483F3-A4E2-408C-863C-AAD8818FDD29Q34510187-946BFD73-3C48-4BE5-BB0D-743A469A7AA5Q34620664-3591C9E6-B137-4D19-897D-4B1BCAD432FEQ34640536-9F9BF066-2E7C-46AF-ABA9-6560D4E23B1CQ34743488-06511AC5-98CE-4BF2-9D77-0934B89E2C90Q34895561-819CEE94-4D8F-4F65-818A-40A95ADAC4F5Q34927848-4D3DFFAD-130D-4E95-A35F-FE45929850CEQ34982532-B8C56667-2761-4EEE-B8D2-444FE4D74081Q34996659-8FA88AB8-E607-4210-8F42-F03D12B8ACF5Q35127977-37520FE9-EA27-4D01-8E94-EF0E8ACDB9ABQ35159253-2EFAB6CD-C97E-4763-9009-68F4D343FFDFQ35490056-066EB7FA-F17F-45B9-ADC7-12D0D5697F59Q35599802-6604A1BD-251C-4061-9BCA-F1026C521FF4Q35605853-15F803E5-A01C-40AB-9211-1E339F636616Q35640784-56417C79-81C9-4F98-BD1B-55D1EFBB129FQ35710898-67ABDF72-C30D-424B-925A-6394C9F631A1
P2860
Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Acute myeloid leukemia or myel ...... cancer adjuvant chemotherapy.
@en
Acute myeloid leukemia or myel ...... cancer adjuvant chemotherapy.
@nl
type
label
Acute myeloid leukemia or myel ...... cancer adjuvant chemotherapy.
@en
Acute myeloid leukemia or myel ...... cancer adjuvant chemotherapy.
@nl
prefLabel
Acute myeloid leukemia or myel ...... cancer adjuvant chemotherapy.
@en
Acute myeloid leukemia or myel ...... cancer adjuvant chemotherapy.
@nl
P2093
P2860
P356
P1476
Acute myeloid leukemia or myel ...... cancer adjuvant chemotherapy.
@en
P2093
Alfred I Neugut
Charles L Bennett
Judith S Jacobson
Russell McBride
Victor R Grann
Wei-Yann Tsai
P2860
P304
P356
10.1093/JNCI/DJK028
P407
P577
2007-02-01T00:00:00Z